THE ARISING · Longevity & Healthspan
A blood test can help guide a new treatment for some advanced breast cancers
The FDA approved giredestrant with everolimus for a specific form of advanced breast cancer. In the relevant trial group, the combination delayed progression; whether it extends life is not yet known.
A blood test can change the next treatment choice for some people whose breast cancer has returned or grown despite endocrine therapy. The test looks for a change in ESR1, the gene that encodes the estrogen receptor. It does that by reading fragments of tumor DNA circulating in the blood.
On November 16, the FDA approved the oral drug giredestrant (Wilserdly) in combination with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated breast cancer that is locally advanced or metastatic. The cancer must have recurred during or after endocrine treatment given after surgery, or progressed after at least one endocrine-based treatment for metastatic disease. The FDA also authorized FoundationOne Liquid CDx as a companion blood test for identifying eligible patients. This approval is not for early-stage disease or for giredestrant by itself.
The phase 3 evERA trial randomly assigned 373 people to giredestrant or an endocrine treatment chosen by their physician. Both groups received everolimus. Trial participants had previously received a CDK4/6 inhibitor plus endocrine therapy. Among the 207 participants with an ESR1 mutation, the median time before the cancer worsened or the participant died was 10.0 months with giredestrant and 5.5 months with the comparison treatment. The hazard ratio was 0.38 (95% confidence interval, 0.27 to 0.54). At the time of that analysis, there were not enough overall survival data to know whether patients lived longer.
The combination has meaningful side effects. Common reactions included mouth sores, rash, fatigue, diarrhea, muscle or joint pain, inflammation in the lungs and nausea. Giredestrant also carries warnings about slow heart rate and potential harm to a developing fetus.
What matters here is the link between the test and the next decision. The blood test does not diagnose breast cancer or predict exactly how long a treatment will work for an individual. It can identify a tumor change that helps the oncology team decide whether an approved treatment is an option.